Incretin Atlas › Trials › CT-388 phase 2
CT-388 phase 2
CT-388 · obesity
Design
- Molecule(s)
- CT-388
- Population
- obesity
- Phase
- 2
- Duration
- 48 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CT-388 24 mg | obesity | 48 | — | −22.7 % vs −0.2 % Δ −22.5 pp | — | — | — | — | — | — | — | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- CT-388 24 mg: Abstract reports up to −22.7 % (absolute) and −22.5 % placebo-adjusted at 24 mg, 48 weeks; placebo derived as −0.2 %
Verbatim quotes from the source (1)
- CT-388 24 mg · weight_eff · Conclusion
CT-388 demonstrated significant, dose-dependent WL of up to 22.7%
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: CT-388 phase 2. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ct-388-phase-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.